DOXAZOSIN MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Doxazosin Mesylate patents expire, and when can generic versions of Doxazosin Mesylate launch?
Doxazosin Mesylate is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Ani Pharms, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Nesher Pharms, Pliva, Rising, Strides Pharma, Teva, Unichem, Upsher Smith Labs, Watson Labs Inc, and Zydus Pharms. and is included in nineteen NDAs.
The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doxazosin Mesylate
A generic version of DOXAZOSIN MESYLATE was approved as doxazosin mesylate by APOTEX on October 18th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DOXAZOSIN MESYLATE?
- What are the global sales for DOXAZOSIN MESYLATE?
- What is Average Wholesale Price for DOXAZOSIN MESYLATE?
Summary for DOXAZOSIN MESYLATE
| US Patents: | 0 |
| Applicants: | 18 |
| NDAs: | 19 |
| Finished Product Suppliers / Packagers: | 28 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,730 |
| Drug Prices: | Drug price information for DOXAZOSIN MESYLATE |
| What excipients (inactive ingredients) are in DOXAZOSIN MESYLATE? | DOXAZOSIN MESYLATE excipients list |
| DailyMed Link: | DOXAZOSIN MESYLATE at DailyMed |
See drug prices for DOXAZOSIN MESYLATE
Recent Clinical Trials for DOXAZOSIN MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Pfizer | |
| University of Minnesota - Clinical and Translational Science Institute | Phase 2 |
Pharmacology for DOXAZOSIN MESYLATE
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for DOXAZOSIN MESYLATE
Anatomical Therapeutic Chemical (ATC) Classes for DOXAZOSIN MESYLATE
US Patents and Regulatory Information for DOXAZOSIN MESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs Inc | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075426-004 | Oct 18, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pliva | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075750-001 | Jun 8, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Heritage Pharma | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 205210-004 | Feb 13, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Strides Pharma | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 076161-001 | Jun 10, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075536-004 | Oct 18, 2000 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Rising | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 212727-001 | Mar 15, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
